Filtered By:
Specialty: Biomedical Science
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 5325 results found since Jan 2013.
Convergent activation of two-pore channels mediated by the NAADP-binding proteins JPT2 and LSM12
Sci Signal. 2023 Aug 22;16(799):eadg0485. doi: 10.1126/scisignal.adg0485. Epub 2023 Aug 22.ABSTRACTThe second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) evokes calcium ion (Ca2+) release from endosomes and lysosomes by activating two-pore channels (TPCs) on these organelles. Rather than directly binding to TPCs, NAADP associates with proteins that indirectly confer NAADP sensitivity to the TPC complex. We investigated whether and how the NAADP-binding proteins Jupiter microtubule-associated homolog 2 (JPT2) and like-Sm protein 12 (LSM12) contributed to NAADP-TPC-Ca2+ signaling in human cells. Biochemic...
Source: Science Signaling - August 22, 2023 Category: Biomedical Science Authors: Gihan S Gunaratne Eugen Brailoiu Sushil Kumar Yu Yuan James T Slama Timothy F Walseth Sandip Patel Jonathan S Marchant Source Type: research
Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
by Mafalda Cacciottolo, Yujia Li, Justin B. Nice, Michael J. LeClaire, Ryan Twaddle, Ciana L. Mora, Stephanie Y. Adachi, Meredith Young, Jenna Angeles, Kristi Elliott, Minghao Sun
Exosomes are emerging as potent and safe delivery carriers for use in vaccinology and therapeutics. A better vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to provide improved, broader, longer lasting neutralization of SARS-CoV-2, a more robust T cell response, enable widespread global usage, and further enhance the safety profile of vaccines given the likelihood of repeated booster vaccinations. Here, we use ...
Source: PLoS One - August 22, 2023 Category: Biomedical Science Authors: Mafalda Cacciottolo Source Type: research
Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea
by Jieun Jang, Hyopin Jeong, Bong-Hwa Kim, Sura An, Hye-Ryun Yang, Sunjoo Kim
ObjectivesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness in coronavirus disease (COVID-19) patients with breakthrough infections has not been established in South Korea. To address this, we assessed the impact of vaccination on symptom occurrence and viral load. MethodsWe performed a retrospective cohort study of 9,030 COVID-19 patients enrolled between February and November 2021. The impact of vaccination on the incidence of symptoms and viral load as indicated by cycle threshold (Ct) values ofRdRp andE genes ...
Source: PLoS One - August 16, 2023 Category: Biomedical Science Authors: Jieun Jang Source Type: research
Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
Sci Signal. 2023 Aug 15;16(798):eabk3516. doi: 10.1126/scisignal.abk3516. Epub 2023 Aug 15.ABSTRACTThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for strategies to rapidly develop neutralizing monoclonal antibodies that can function as prophylactic and therapeutic agents and to help guide vaccine design. Here, we demonstrate that engineering approaches can be used to refocus an existing antibody that neutralizes one virus but not a related virus. Through a rapid affinity maturation strategy, we engineered CR3022, a SARS-CoV-1-neutralizing antibody, to bind to the receptor...
Source: Science Signaling - August 15, 2023 Category: Biomedical Science Authors: Fangzhu Zhao Meng Yuan Celina Keating Namir Shaabani Oliver Limbo Collin Joyce Jordan Woehl Shawn Barman Alison Burns Quoc Tran Xueyong Zhu Michael Ricciardi Linghang Peng Jessica Smith Deli Huang Bryan Briney Devin Sok David Nemazee John R Teijaro Ian A Source Type: research
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
CONCLUSION: As the COVID-19 variants and risk group-specific durable efficacy, toxicity (and/or resistance) and optimal dosing of Evusheld remain uncertain, better empirical estimates to inform these values in different epidemiological contexts are needed. These results may help decision-makers prioritize resources toward more equitable and effective COVID-19 control efforts.PMID:37582500 | DOI:10.3346/jkms.2023.38.e250
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Youngji Jo Sun Bean Kim Jaehun Jung Source Type: research
Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
Sci Signal. 2023 Aug 15;16(798):eabk3516. doi: 10.1126/scisignal.abk3516. Epub 2023 Aug 15.ABSTRACTThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for strategies to rapidly develop neutralizing monoclonal antibodies that can function as prophylactic and therapeutic agents and to help guide vaccine design. Here, we demonstrate that engineering approaches can be used to refocus an existing antibody that neutralizes one virus but not a related virus. Through a rapid affinity maturation strategy, we engineered CR3022, a SARS-CoV-1-neutralizing antibody, to bind to the receptor...
Source: Science Signaling - August 15, 2023 Category: Biomedical Science Authors: Fangzhu Zhao Meng Yuan Celina Keating Namir Shaabani Oliver Limbo Collin Joyce Jordan Woehl Shawn Barman Alison Burns Quoc Tran Xueyong Zhu Michael Ricciardi Linghang Peng Jessica Smith Deli Huang Bryan Briney Devin Sok David Nemazee John R Teijaro Ian A Source Type: research
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From a Survey of Patient-Reported Outcomes After Vaccination
CONCLUSION: The results of the survey of patients with ARD revealed that patient-reported AEs and underlying disease flares after receiving the COVID-19 vaccine were significantly higher than those after the influenza vaccine.PMID:37582497 | DOI:10.3346/jkms.2023.38.e247
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Ji-Won Kim Ju-Yang Jung Chang-Hee Suh Young-Min Ye Hyoun-Ah Kim Source Type: research
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
CONCLUSION: As the COVID-19 variants and risk group-specific durable efficacy, toxicity (and/or resistance) and optimal dosing of Evusheld remain uncertain, better empirical estimates to inform these values in different epidemiological contexts are needed. These results may help decision-makers prioritize resources toward more equitable and effective COVID-19 control efforts.PMID:37582500 | DOI:10.3346/jkms.2023.38.e250
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Youngji Jo Sun Bean Kim Jaehun Jung Source Type: research
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From a Survey of Patient-Reported Outcomes After Vaccination
CONCLUSION: The results of the survey of patients with ARD revealed that patient-reported AEs and underlying disease flares after receiving the COVID-19 vaccine were significantly higher than those after the influenza vaccine.PMID:37582497 | DOI:10.3346/jkms.2023.38.e247
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Ji-Won Kim Ju-Yang Jung Chang-Hee Suh Young-Min Ye Hyoun-Ah Kim Source Type: research
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
CONCLUSION: As the COVID-19 variants and risk group-specific durable efficacy, toxicity (and/or resistance) and optimal dosing of Evusheld remain uncertain, better empirical estimates to inform these values in different epidemiological contexts are needed. These results may help decision-makers prioritize resources toward more equitable and effective COVID-19 control efforts.PMID:37582500 | PMC:PMC10427216 | DOI:10.3346/jkms.2023.38.e250
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Youngji Jo Sun Bean Kim Jaehun Jung Source Type: research
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From a Survey of Patient-Reported Outcomes After Vaccination
CONCLUSION: The results of the survey of patients with ARD revealed that patient-reported AEs and underlying disease flares after receiving the COVID-19 vaccine were significantly higher than those after the influenza vaccine.PMID:37582497 | PMC:PMC10427213 | DOI:10.3346/jkms.2023.38.e247
Source: Journal of Korean Medical Science - August 15, 2023 Category: Biomedical Science Authors: Ji-Won Kim Ju-Yang Jung Chang-Hee Suh Young-Min Ye Hyoun-Ah Kim Source Type: research
